Genelux Corp GNLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.89–3.04
- 52-Week Range
- $2.29–8.54
- Bid/Ask
- $2.92 / $3.00
- Shares Outstanding
- 44.84M
- Market Cap
- $135.87M
- Volume/Avg
- 248,646 / 173,408
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.genelux.com
Valuation
|
Metric
|
GNLX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.82 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GNLX
|
|---|---|
Quick Ratio | 3.60 |
Current Ratio | 3.68 |
Interest Coverage | — |
Quick Ratio
GNLX
Profitability
|
Metric
|
GNLX
|
|---|---|
Return on Assets (Normalized) | −91.02% |
Return on Equity (Normalized) | −125.80% |
Return on Invested Capital (Normalized) | −119.98% |
Return on Assets
GNLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$WYV!P# | LOCK|NCm$ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Lj>C$^# | LOCK|>DNl | $70B | |||
| argenx SE ADR
ARGX
| LOCK|pG%%>S | LOCK|zlK | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#?&J<! | LOCK|b>gYc | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|kKnM#^ | LOCK|LKY | $36B | |||
| Moderna Inc
MRNA
| LOCK|<LJ>TFm | LOCK|wXc | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Ld<?GnD@ | LOCK|?vv@@ | $25B | |||
| Incyte Corp
INCY
| LOCK|WYn%rWZ | LOCK|nM | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&L#@%z | LOCK|Rb | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|CKvN!@ | LOCK|^SM | $17B |
United States